The Potential of Mesenchymal Stem Cells in Treating Spinocerebellar Ataxia: Advances and Future Directions

Overview

Journal Biomedicines

Specialty Biomedical Engineering

Date 2024 Nov 27

PMID 39595073

Authors

Gi Beom Lee

Se Min Park

Un Ju Jung

Sang Ryong Kim

Affiliations

Soon will be listed here.

Abstract

Spinocerebellar ataxia (SCA) is a heterogeneous disorder characterized by impaired balance and coordination caused by cerebellar dysfunction. The absence of treatments approved by the U.S. Food and Drug Administration for SCA has driven the investigation of alternative therapeutic strategies, including stem cell therapy. Mesenchymal stem cells (MSCs), known for their multipotent capabilities, have demonstrated significant potential in treating SCA. This review examines how MSCs may promote neuronal growth, enhance synaptic connectivity, and modulate brain inflammation. Recent findings from preclinical and clinical studies are also reviewed, emphasizing the promise of MSC therapy in addressing the unmet needs of SCA patients. Furthermore, ongoing clinical trials and future directions are proposed to address the limitations of the current approaches.

References

Chun Y, Chaudhari P, Jang Y . Applications of patient-specific induced pluripotent stem cells; focused on disease modeling, drug screening and therapeutic potentials for liver disease. Int J Biol Sci. 2010; 6(7):796-805. PMC: 3005346. DOI: 10.7150/ijbs.6.796. View

Blandini F, Cova L, Armentero M, Zennaro E, Levandis G, Bossolasco P . Transplantation of undifferentiated human mesenchymal stem cells protects against 6-hydroxydopamine neurotoxicity in the rat. Cell Transplant. 2009; 19(2):203-17. DOI: 10.3727/096368909X479839. View

Wang Y, Muraleetharan A, Langiu M, Gregory K, Hellyer S . SCA44- and SCAR13-associated GRM1 mutations affect metabotropic glutamate receptor 1 function through distinct mechanisms. Br J Pharmacol. 2024; 181(22):4514-4530. DOI: 10.1111/bph.16510. View

Parkinson M, Schulz J, Giunti P . Co-enzyme Q10 and idebenone use in Friedreich's ataxia. J Neurochem. 2013; 126 Suppl 1:125-41. DOI: 10.1111/jnc.12322. View

Gronthos S, Zannettino A, Hay S, Shi S, Graves S, Kortesidis A . Molecular and cellular characterisation of highly purified stromal stem cells derived from human bone marrow. J Cell Sci. 2003; 116(Pt 9):1827-35. DOI: 10.1242/jcs.00369. View

Zargarani S, Tavaf M, Soltanmohammadi A, Yazdanpanah E, Baharlou R, Yousefi B . Adipose-derived mesenchymal stem cells ameliorates experimental autoimmune encephalomyelitis via modulation of Th1/Th17 and expansion of Th2/Treg responses. Cell Biol Int. 2024; 48(8):1124-1137. DOI: 10.1002/cbin.12171. View

Volarevic V, Markovic B, Gazdic M, Volarevic A, Jovicic N, Arsenijevic N . Ethical and Safety Issues of Stem Cell-Based Therapy. Int J Med Sci. 2018; 15(1):36-45. PMC: 5765738. DOI: 10.7150/ijms.21666. View

Perez B, Shorrock H, Banez-Coronel M, Zu T, Romano L, Laboissonniere L . CCG•CGG interruptions in high-penetrance SCA8 families increase RAN translation and protein toxicity. EMBO Mol Med. 2021; 13(11):e14095. PMC: 8573593. DOI: 10.15252/emmm.202114095. View

Mohammadzadeh A, Lahouty M, Charkhian H, Ghafour A, Moazzendizaji S, Rezaei J . Human umbilical cord mesenchymal stem cell-derived exosomes alleviate the severity of experimental autoimmune encephalomyelitis and enhance lag-3 expression on foxp3 + CD4 + T cells. Mol Biol Rep. 2024; 51(1):522. DOI: 10.1007/s11033-024-09433-5. View

10.

Dongmei H, Jing L, Mei X, Ling Z, Hongmin Y, Zhidong W . Clinical analysis of the treatment of spinocerebellar ataxia and multiple system atrophy-cerebellar type with umbilical cord mesenchymal stromal cells. Cytotherapy. 2011; 13(8):913-7. DOI: 10.3109/14653249.2011.579958. View

11.

Klockgether T . Sporadic ataxia with adult onset: classification and diagnostic criteria. Lancet Neurol. 2010; 9(1):94-104. DOI: 10.1016/S1474-4422(09)70305-9. View

12.

Fujiwara M, Raheja R, Garo L, Ajay A, Kadowaki-Saga R, Karandikar S . microRNA-92a promotes CNS autoimmunity by modulating the regulatory and inflammatory T cell balance. J Clin Invest. 2022; 132(10). PMC: 9106347. DOI: 10.1172/JCI155693. View

13.

Hernandez A, Garcia E . Mesenchymal Stem Cell Therapy for Alzheimer's Disease. Stem Cells Int. 2021; 2021:7834421. PMC: 8426054. DOI: 10.1155/2021/7834421. View

14.

Alavi O, Alizadeh A, Dehghani F, Alipour H, Tanideh N . Anti-inflammatory Effects of Umbilical Cord Mesenchymal Stem Cell and Autologous Conditioned Serum on Oligodendrocyte, Astrocyte, and Microglial Specific Gene in Cuprizone Animal Model. Curr Stem Cell Res Ther. 2023; 19(1):71-82. DOI: 10.2174/1574888X18666230228102731. View

15.

Lukomska B, Stanaszek L, Zuba-Surma E, Legosz P, Sarzynska S, Drela K . Challenges and Controversies in Human Mesenchymal Stem Cell Therapy. Stem Cells Int. 2019; 2019:9628536. PMC: 6481040. DOI: 10.1155/2019/9628536. View

16.

Swinnen B, Robberecht W, Van Den Bosch L . RNA toxicity in non-coding repeat expansion disorders. EMBO J. 2019; 39(1):e101112. PMC: 6939197. DOI: 10.15252/embj.2018101112. View

17.

Toh W, Lai R, Zhang B, Lim S . MSC exosome works through a protein-based mechanism of action. Biochem Soc Trans. 2018; 46(4):843-853. PMC: 6103455. DOI: 10.1042/BST20180079. View

18.

Miranda C, Marcelo A, Silva T, Barata J, Vasconcelos-Ferreira A, Pereira D . Repeated Mesenchymal Stromal Cell Treatment Sustainably Alleviates Machado-Joseph Disease. Mol Ther. 2018; 26(9):2131-2151. PMC: 6127516. DOI: 10.1016/j.ymthe.2018.07.007. View

19.

Schmitz-Hubsch T, Tezenas Du Montcel S, Baliko L, Berciano J, Boesch S, Depondt C . Scale for the assessment and rating of ataxia: development of a new clinical scale. Neurology. 2006; 66(11):1717-20. DOI: 10.1212/01.wnl.0000219042.60538.92. View

20.

Levenberg S, Zoldan J, Basevitch Y, Langer R . Endothelial potential of human embryonic stem cells. Blood. 2007; 110(3):806-14. PMC: 1924772. DOI: 10.1182/blood-2006-08-019190. View